Table 3.
H&E-TILs, the short-term response to CCRT and survival
| Pre-PSM(n = 160) | Post-PSM(n = 121) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total | H&E-TILs (+) | H&E-TILs (-) | P | Total | H&E-TILs (+) | H&E-TILs (-) | P | |
| Response to radiotherapy | 0.001 | 0.021 | ||||||
| CR | 49 | 30 | 19 | 37 | 20 | 17 | ||
| PR | 56 | 33 | 23 | 44 | 24 | 20 | ||
| SD | 46 | 15 | 31 | 33 | 9 | 24 | ||
| PD | 9 | 2 | 7 | 7 | 1 | 6 | ||
| CR + PR | 105 | 63 | 42 | 0.001 | 81 | 44 | 37 | 0.002 |
| SD + PD | 55 | 17 | 38 | 40 | 10 | 30 | ||
| 1, 3, 5-year OS (%) | 69.8,35.2, 23.2 | 84.3,47.4,34.5 | 54.0, 20.8, 0 | 0.001 | 69.8,35.2,23.2 | 84.5,53.4,34.8 | 57.8,20.6,0 | 0.001 |
| 1, 3, 5-year PFS (%) | 44.9, 22.1,18.8 | 65.2, 35.1, 28.8 | 23.5, 8.8, 0 | 0.001 | 44.9,22.1,18.8 | 59.7,40.0,34.3 | 36.5,8.6,0 | 0.001 |
| 1, 3, 5-year DMFS (%) | 74.4,56.0, 45,2 | 85.5, 64.9, 48,7 | 60.7, 46.3, 0 | 0.001 | 74.4,56.0,45,2 | 80.6,68.8,34.4 | 63.9,43.9,0 | 0.002 |
| 1, 3, 5-year LRFS (%) | 56.6,35.2, 29.5 | 72.4, 46.5, 33.5 | 39.1, 19.2, 0 | 0.001 | 56.6,35.2,29.5 | 70.0,52.3,44.9 | 44.1,19.5,0 | 0.001 |
| mOS (months) | 25 | 36 | 15 | 0.001 | 43 | 16 | 0.001 | |
| mPFS (months) | 8 | 21 | 4 | 0.001 | 21 | 4 | 0.001 | |
| mDMFS (months) | 60 | 88 | 32 | 0.001 | 88 | 26 | 0.002 | |
| mLRFS (months) | 16 | 35 | 7 | 0.001 | 66 | 8 | 0.001 |
PSM Propensity score matching, CR Complete response, PR: Partial response, SD Stable disease, PD Progressive disease, OS Overall Survival, PFS Progression-free Survival, DMFS Distant Metastasis-free Survival, LRFS Locoregional Recurrence-free survival, mOS Median Overall Survival, mPFS Median Progression-free Survival, mDMFS Median Distant Metastasis-free Survival, mLRFS Median Locoregional Recurrence-free survival